当归龙荟片联合普芦卡必利治疗慢性功能性便秘的临床研究

目的探讨当归龙荟片联合普芦卡必利治疗慢性功能性便秘的临床疗效。方法选取2018年5月-2019年5月在北京市肛肠医院治疗的慢性功能性便秘患者122例,根据用药的差别分为对照组(61例)和治疗组(61例)。对照组口服琥珀酸普芦卡必利片,2mg/次,1次/d;治疗组在对照组基础上口服当归龙荟片,4片/次,2次/d。两组患者均经4周治疗。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状评分、PAC-QOL积分、结肠传输试验积分、Bristol和SF-36评分,及血清5-羟色胺(5-HT)、血管活性肠肽(VIP)、P物质(SP)和一氧化氮(NO)水平。结果治疗后,对照组和治疗组临床有效率分别为80.33%和96.72%,两组比较差异具有统计学意义(P<0.05)。经治疗,两组症状积分均明显降低(P<0.05),且治疗组比对照组降低更明显(P<0.05)。经治疗,两组患者PAC-QOL积分和结肠传输试验积分明显降低(P<0.05),而Bristol和SF-36评分明显升高(P<0.05),且治疗组患者明显好于对照组(P<0.05)。经治疗,两组患者血清SP、5-HT水平均显著升高(P<0.05),而VIP和NO水平均明显降低(P<0.05),且治疗组患者SP、5-HT、VIP和NO水平明显优于对照组(P<0.05)。结论当归龙荟片联合普芦卡必利治疗慢性功能性便秘可有效改善患者临床症状,促进患者生活质量改善,具有一定的临床推广应用价值。

Clinical study on Danggui Longhui Tablets combined with procapril in treatment of chronic functional constipation

Objective To investigate the clinical efficacy of Danggui Longhui Tablets combined with procapril in treatment of chronic functional constipation. Methods Patients (122 cases) with chronic functional constipation in Beijing Rectum Hospital from May 2018 to May 2019 were divided into control (61 cases) and treatment (61 cases) groups based on different treatments. Patients in the control group were po administered with Prucalopride Succinate Tablets, 2 mg/time, once daily. Patients in the treatment group were po administered with Danggui Longhui Tablets on the basis of the control group, 4 tablets/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom score, PAC-QOL score, colonic transit test score, Bristol and SF-36 score, and the serum level of 5-HT, VIP, SP and NO in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.33% and 96.72% respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom score in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the PAC-QOL score and colonic transit test score in two groups were significantly decreased (P<0.05), but the Bristol and SF-36 score were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum level of 5-HT and SP in two groups was significantly increased (P<0.05), but the VIP and NO level was significantly decreased (P<0.05), and the serum level of 5-HT, VIP, SP, and NO in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Danggui Longhui Tablets combined with procapril in treatment of chronic functional constipation can effectively improve the clinical symptoms, and promote the improvement of quality of life, which has a certain clinical application value.